In this study, pro-FTY (the first S1P-targeting inhibitor that does not cause lymphocytopenia) was administered using a novel DDS in which the prodrug is converted to the active drug after interacting with acrolein, which is highly expressed in cancer cells. The gene discussed is MBTPS1; the disease is cancer.